araag2/HINT huggingface dataset:
Clinical trial NCT00372073 (phase 2, status: terminated)
Conditions: non-small cell lung cancer
ICD codes: C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, C34.2
Drugs: seliciclib, placebo
SMILES: CC[C@H](CO)NC1=NC(NCC2=CC=CC=C2)=C2N=CN(C(C)C)C2=N1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Adult patients with histologically-confirmed recurrent non-small cell lung cancer have
             had at least two prior systemic treatment regimens

          -  Must have measurable disease according to RECIST

          -  Eastern Cooperative Oncology Group performance status 0-1

          -  Adequate bone marrow, hepatic and renal function

          -  Ability to swallow capsules

          -  At least 3 weeks from prior systemic treatments including investigational anti-cancer
             therapy, at least 7 days from prior radiation therapy and have recovered from prior
             toxicities

          -  At least 3 weeks from major surgery

        Exclusion Criteria:

          -  Non-small cell cancer histology contains a component of small cell lung cancer

          -  Previously untreated CNS metastasis or progressive CNS metastasis

          -  Prior treatment with a CDK inhibitor

          -  Currently receiving radiotherapy, biological therapy, or any other investigational
             therapy

          -  Uncontrolled intercurrent illness

          -  Having other cancers that have been treated with chemotherapy or biological therapy in
             the past 5 years with the exception of adequately treated in situ cervical cancer or
             basal cell skin cancer

          -  Pregnant or lactating women

          -  Known to be HIV-positive

          -  Active hepatitis B and/or hepatitis C infection
Clinical trial NCT00503516 (phase 2/phase 3, status: terminated)
Conditions: dementia
ICD codes: G31.09, G31.83, F01.50, F01.51, F03.90, F03.91, F18.17
Drugs: megestrol acetate, placebo
SMILES: [H][C@@]12CC[C@](OC(C)=O)(C(C)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])C=C(C)C2=CC(=O)CC[C@]12C, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Reason stopped: 
    difficulties to recruit the patients following the inclusion criteria
  
Eligibility criteria:

        Inclusion Criteria:

          -  Patients diagnosed of primary or mixed dementia (CIE 10criteria)

          -  Weihgt loss >5% of habitual weight in the last 6 months and proteic-caloric
             malnutrition (MNA <17)

          -  Outpatients

          -  Patients that accept the participation in the study

        Exclusion Criteria:

          -  Vascular pure Dementia and secondary dementias( vascular dementia, Parkinson
             disease,etc)

          -  Dementia in a terminal phase: category of FAST 7c in the Reisber scale

          -  Concomitant treatment with steroids, androgens or other drugs with progestagens

          -  Weight loss secondary to neoplasia
Clinical trial NCT00654420 (phase 2, status: completed)
Conditions: carcinoma, non-small-cell lung
ICD codes: D02.20, D02.21, D02.22
Drugs: dalotuzumab, erlotinib
SMILES: COCCOC1=CC2=C(C=C1OCCOC)C(NC1=CC(=CC=C1)C#C)=NC=N2
Eligibility criteria:

        Inclusion Criteria:

          -  Participant has locally advanced or metastatic stage IIIB/IV NSCLC that has relapsed
             after hemotherapy/chemoratiotherapy

          -  Participant has had at least one chemotherapy regimen for recurrent or metastatic
             disease

          -  Participant is 18 years of age or older

          -  Participant has a performance status of 0-2 on Eastern Cooperative Group (ECOG) scale

          -  Women of childbearing potential have a negative pregnancy test

        Exclusion Criteria:

          -  Participant has had chemotherapy within 2 weeks or biological therapy (e.g.
             bevacizumab) within 4 weeks

          -  Participant has not recovered from adverse events from previous therapy within 4 weeks

          -  Participant has received EGFR-Tyrosine Kinase Inhibitor (TKI) inhibitor/anti-EGFR mAb
             therapy

          -  Participant has received IGF1R-TKI inhibitor/anti-IGF1R mAB therapy

          -  Participant has had more than 2 systemic chemotherapies for metastatic disease

          -  Participant has not completed radiotherapy with complete resolution of toxicities at
             least 2 weeks before starting in the study

          -  Participant is taking part in another clinical study

          -  Participant has a primary central nervous system tumor

          -  Participant abuses drugs or alcohol

          -  Participant is pregnant or breastfeeding

          -  Participant is Human Immunodeficiency Virus (HIV) positive

          -  Participant has a history of hepatitis B or C

          -  Participant is using growth hormone or growth hormone inhibitors
Clinical trial NCT01018875 (phase 2, status: completed)
Conditions: alzheimer's disease
ICD codes: G30.8, G30.9, G30.0, G30.1
Drugs: abt-288, donepezil, placebo
SMILES: O=S(=O)(C1=CC=CC=C1)C1=CN=C2C(C=CC=C2N2CCNCC2)=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria: 1. Have voluntarily signed an informed consent. 2. Subject meets
        diagnostic criteria criteria for probable AD (Alzheimer's Disease). 3. Female subjects must
        be postmenopausal for at least 2 years or surgically sterile. 4. Male subjects must be
        surgically sterile, sexually inactive or using a barrier method of birth control. 5.
        Subject has an identified, reliable caregiver. 6. Subject has a CT or MRI scan within 36
        months prior to randomization. 7. With the exception of a diagnosis of mild-to-moderate AD
        and the presence of stable medical conditions, the subject is generally in good health
        based on medical history, physical examination, vital signs, clinical lab tests and ECG
        Exclusion Criteria: 1. Subject is currently taking or has taken a medication for the
        treatment of AD or dementia with 60 days of Screening visit, or is participating in
        cognitive therapy for the treatment of AD or dementia. 2. Subject uses non-prescribed drugs
        of abuse or has a history of drug or alcohol abuse/dependence. 3. Subject has a history of
        any significant neurologic disease other than AD. 4. Subject has a history of intolerance
        or adverse reaction to donepezil that led to discontinuation. 5. Subject has received any
        investigation product within 6 weeks prior to study drug administration.
Clinical trial NCT00385437 (phase 2, status: completed)
Conditions: depression, excessive daytime sleepiness
ICD codes: F32.A, F53.0, P91.4, Z13.31, Z13.32, M26.23, K03.0, M26.07, N92.2, Z62.6, K13.23, R68.11
Drugs: mirtazapine treatment
SMILES: CN1CCN2C(C1)C1=CC=CC=C1CC1=C2N=CC=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Fulfilling DSM-IV criteria for Major Depressive Disorder

          -  Score of Hamilton Rating Scale for Depression (HDRS-17) > 17

          -  Patient to be prescribed mirtazapine (Remeron) as determined by physician

          -  Subject has no known clinically significant abnormal vital signs or other clinical
             findings at screening.

          -  Patients should have a driving license for more than 3 years and drive over 15,000 km
             year.

          -  Females of childbearing potential must willingly use effective birth control.

        Exclusion Criteria:

          -  Night shift workers.

          -  A history or present condition of: Bipolar Disorder or Depressive Disorder not
             Otherwise Specified,Schizophrenia or other psychotic disorders (according to DSM-IV),
             Schizotypal or Borderline personality disorder, Organic mental disorders

          -  A present condition of: Anxiety Disorders (according to DSM-IV), Eating Disorders,
             Postpartum Depression

          -  Epilepsy or a history of seizure disorder or ever received treatment with
             anticonvulsant medication for epilepsy or seizures

          -  PSG recording of an extremely abnormal sleep EEG (other than that which would be
             expected with depression)

          -  Alcohol or substance abuse (according to DSM-IV) during the last 6months prior to
             baseline.

          -  Any physical disease, which may explain the symptoms of depression.

          -  Any chronic physical disease, which is not stabilized.
Clinical trial NCT01012895 (phase 2, status: completed)
Conditions: chronic hepatitis c
ICD codes: B18.2, B18.0, B18.1, B18.8, B18.9, K71.3, K71.4
Drugs: bms-790052, bms-650032, bms-650032, bms-650032, pegylated-interferon alfa-2a, ribavirin
SMILES: COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C1=NC=C(N1)C1=CC=C(C=C1)C1=CC=C(C=C1)C1=CN=C(N1)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)OC)C(C)C, COC1=CN=C(O[C@@H]2C[C@H](N(C2)C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)C(=O)N[C@@]2(C[C@H]2C=C)C(=O)NS(=O)(=O)C2CC2)C2=C1C=CC(Cl)=C2, COC1=CN=C(O[C@@H]2C[C@H](N(C2)C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)C(=O)N[C@@]2(C[C@H]2C=C)C(=O)NS(=O)(=O)C2CC2)C2=C1C=CC(Cl)=C2, COC1=CN=C(O[C@@H]2C[C@H](N(C2)C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)C(=O)N[C@@]2(C[C@H]2C=C)C(=O)NS(=O)(=O)C2CC2)C2=C1C=CC(Cl)=C2, NC(=O)C1=NN(C=N1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O
Eligibility criteria:

        Inclusion Criteria:

          -  Male and female subjects ages 18 to 70 years

          -  HCV-Infected Genotype 1 Null responders to current standard of care

          -  Expansion Cohorts A1 and A2 are restricted to patients infected with HCV Genotype 1b
             only.

        Exclusion Criteria:

          -  Evidence of a medical condition associate with chronic liver disease other than HCV

          -  History of variceal bleeding, hepatic encephalopathy, or ascites requiring management
             with diuretics or paracentesis

          -  History of Cancer within 5 years of enrollment

          -  History of gastrointestinal disease or surgical procedure (except Cholecystectomy)

          -  History of clinically significant cardiac disease

          -  History of Glucose-6-phosphate dehydrogenase (G6PD) deficiency

          -  Documented cirrhosis within 12 months prior to dosing

          -  Positive for Human Immunodeficiency Virus (HIV) or Hepatitis B Virus (HBV)

          -  Pregnant
Clinical trial NCT01203644 (phase 2, status: completed)
Conditions: inguinal hernia
ICD codes: K40.11, K40.41, K40.01, K40.21, K40.31, K40.91, K40.10
Drugs: sky0402, bupivacaine hcl
SMILES: CCCCN1CCCCC1C(=O)NC1=C(C)C=CC=C1C, CCCCN1CCCCC1C(=O)NC1=C(C)C=CC=C1C
Eligibility criteria:

        Inclusion Criteria:

          1. Males ≥18 years of age at the Screening visit.

          2. Scheduled to undergo unilateral inguinal hernia repair under general anesthesia, using
             an open, tension free procedure (e.g., Lichtenstein technique with or without mesh).

          3. American Society of Anesthesiology (ASA) Physical Class 1 or 2.

          4. Able and willing to comply with all study visits and procedures.

          5. Capable of speaking and understanding the local language sufficiently to provide
             responses to pain assessment scales.

          6. Willing and capable of providing written informed consent.

        Exclusion Criteria:

          1. Clinically significant electrocardiogram abnormalities at Screening or on Day 1 (pre
             administration).

          2. Albumin and/or alpha 1 acid glycoprotein (AAG) below normal levels.

          3. Current or historical evidence of any clinically significant disease or condition
             that, in the opinion of the Investigator, might have increased the risk of surgery or
             complicated the subject's postoperative course.

          4. Opioid medication usage during the 7 day period preceding the administration of study
             drug.

          5. Current medical conditions that could have required treatment with analgesic
             medications in the postoperative period for pain that was not surgically related
             (e.g., rheumatoid arthritis).

          6. Body mass index >30 kg/m^2

          7. Body weight <60 kg.

          8. History of hypersensitivity or idiosyncratic reaction to amide type local anesthetic
             agents.

          9. History of hypersensitivity, idiosyncratic reactions, and other contraindications to
             the pain control agents (opioid or non-opioid) anticipated to be used postoperatively.
             These contraindications may have included: angioedema and bronchospastic reactivity to
             non steroidal anti inflammatory drug, peptic ulcer (active within the last three
             months), hepatic or renal insufficiency.

         10. Coagulation disorders or ongoing anticoagulation treatment.

         11. Administration of an investigational drug within 30 days or five half lives (of
             elimination), whichever was longer, prior to study drug administration.

         12. Suspected or known history of substance abuse and/or alcoholism.

         13. Clinically significant complications during the hernia repair surgery (e.g., excessive
             bleeding), which might have rendered the subject medically unstable or might have
             complicated the subject's postoperative course.
Clinical trial NCT00537420 (phase 2, status: completed)
Conditions: obesity
ICD codes: E66.8, E66.9, E66.1, O99.214, O99.215, O99.210, O99.211
Drugs: nasal placebo, placebo capsule, pyy3-36, pyy3-36, pyy3-36, sibutramine
SMILES: [Na+].[Cl-], CC1=CC(O)=CC(C)=C1Cl, CC(C)CC(N(C)C)C1(CCC1)C1=CC=C(Cl)C=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Male or Female patients 18 and 65 years, inclusive;

          -  BMI 30-43 kg/m2, inclusive;

          -  In good health, determined by medical history and physical examination, as well as
             normal 12-lead ECG and vital signs;

          -  Non-smoker and no use of tobacco or nicotine products for at least 3 months;

          -  Females will be non-pregnant, non-lactating, and either post-menopausal for at least 1
             year, surgically sterile (including tubal ligation, hysterectomy) for at least 3
             months, until 30 days following Study Completion be willing to use an approved method
             of contraception;

          -  Has normal nasal mucosa.

        Exclusion Criteria:

          -  Previous surgical treatment for obesity;

          -  Serious Medical Condition

          -  Serious Psychiatric illness

          -  Organic causes of obesity (e.g. untreated hypothyroidism)

          -  Type 1 or Type 2 Diabetes;

          -  Presence of uncontrolled hypertension

          -  On prohibited concomitant medication
Clinical trial NCT01073228 (phase 2, status: completed)
Conditions: alzheimer's disease, central nervous system diseases, cognition
ICD codes: G30.8, G30.9, G30.0, G30.1, G37.9, G37.3, G13.1, G09, G13.8, G37.8
Drugs: evp-6124, placebo
SMILES: ClC1=C2SC(=CC2=CC=C1)C(=O)N[C@H]1CN2CCC1CC2, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Subjects with Probable Alzheimer's disease

          -  Mini-Mental State Examination (MMSE) score of 14 to 24 inclusive at screening and a
             CDR-SB score ≥2 at the screening assessment

          -  Modified Hachinski Ischemic Score (mHIS) ≤4 at screening

          -  Female subjects are ≥1 year post-menopausal or are surgically sterile

          -  Caregiver available; if not living in the same household, caregiver sees subject at
             least four times each week

          -  Subject living at home, senior residential setting, or an institutional setting
             without the need for continuous nursing care

          -  General health status acceptable for participation in a 24 week clinical trial be
             administered

        Exclusion Criteria:

        General

          -  Participation in another therapeutic clinical trial within 30 days before Baseline

          -  Prior participation in an amyloid vaccination clinical study

          -  Inability to swallow capsules

          -  Likely inability to complete 24 week study

          -  Inability to be ≥75% compliant with single-blind placebo run-in medication

          -  Inability to adequately perform cognitive tests

          -  History of significant cardiovascular disease

          -  Major depression

          -  Psychosis

          -  History of stroke within 18 months of screening

          -  Head trauma

          -  Inability to perform any screening or baseline evaluations
Clinical trial NCT00565981 (phase 2, status: completed)
Conditions: b-cell chronic lymphocytic leukemia
ICD codes: C91.11, C91.12, C91.10
Drugs: fludarabine phosphate, alemtuzumab
SMILES: NC1=NC(F)=NC2=C1N=CN2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O, N[C@@H](CCCNC(N)=N)C(O)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Male or female patients with CD23+, CD5+, CD19+, light chain monoclonal B CLL

          -  1st or 2nd relapse after fludarabine or any other primary treatment regimen or
             refractory to primary or secondary treatment (including fludarabine) and
             simultaneously indication for treatment according to the NCI Workshop Criteria 1996

          -  Age 19-75

          -  WHO performance score 0-2

          -  Informed consent given by the patient

        Exclusion Criteria:

          -  HIV positive or positive for Hepatitis B or C

          -  active uncontrolled infection

          -  child bearing age without adequate control of fertility, pregnant or lactating women

          -  intolerance towards any ingredient of either oral fludarabine or alemtuzumab

          -  allergy against foreign proteins

          -  previous treatment with alemtuzumab

          -  treatment with an experimental drug within the previous 2 months

          -  second malignant disease (non CLL)

          -  CLL in transformation (Richter syndrome)

          -  decreased kidney-function with creatinine-clearance < 30ml/min

          -  severe concomitant diseases or major organ dysfunctions

          -  patients who are unable to comply with the requirements of the protocol
Clinical trial NCT00611754 (phase 2, status: completed)
Conditions: head and neck cancer
ICD codes: C76.0, C47.0, C49.0, C77.0, D17.0, D21.0, D36.11
Drugs: oxaliplatin, 5-fu
SMILES: [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1
Eligibility criteria:

        Inclusion Criteria:

        Patients aged 18-70 years, with inoperable locally advanced or metastatic squamous cell
        carcinoma of the head and neck (stage III-IV) histologically proven, no prior chemo and/or
        hormone therapy for metastatic disease or local recurrence (adjuvant or neo-adjuvant
        chemotherapy or radio-chemotherapy was allowed if finished since more than 6 months before
        inclusion and cisplatinum total dose used < or=to 300 mg/m² or carboplatinum total dose
        used < or=to 200mg/m²), at least 1 target lesion (measurable in 2 dimensions > or=to 20 mm
        on computed tomography (CT) or magnetic resonance imaging (MRI) evaluated < 15 days before
        start of study treatment, outside of irradiated fields),performance status (PS) < or =to 2
        World Health Organization (WHO), weight loss < 5% normal weight,hemoglobin > or =to 10
        g/dL, neutrophils > or =to 2000/mm3, platelets > or =to 100,000/mm3 , creatinine < or =to
        1.5 x upper limit of normal (ULN), bilirubin < or =to .5 x ULN, alanine amino-transferase
        (ALT)/aspartate amino-transferase (AST)< or =to 2.5 x ULN (5 x ULN if liver metastases),
        clotting: prothrombin time (PT) > or =to 60%. Written informed consent signed by patient
        and doctor prior to all study procedures -

        Exclusion Criteria:

        -
Clinical trial NCT00695565 (phase 2, status: completed)
Conditions: painful diabetic neuropathy
ICD codes: G58.0, G61.1, A52.15, G60.3, G61.82, H46.2, H46.3
Drugs: placebo gel, clonidine topical gel (arc-4558)
SMILES: [H][C@@]12[C@@H](C)C3=C(C(O)=CC=C3)C(=O)C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@]1([H])[C@H]2O, ClC1=CC=CC(Cl)=C1NC1=NCCN1
Eligibility criteria:

        Inclusion Criteria:

          -  has Type 1 or Type 2 diabetes mellitus

          -  has a history of chronic pain attributable to a symmetrical stocking distribution
             neuropathy in the lower extremities for a duration of at least six months but less
             than or equal to five years prior to Screening

        Exclusion Criteria:

          -  has neuropathy secondary to non-diabetic causes

          -  has a significant neurological disorder or a condition that can cause symptoms that
             mimic peripheral neuropathy or might confound assessment of PDN

          -  has other chronic pain with intensity at or greater than the bilateral pain in the
             feet/toes

          -  is using an implanted medical device (eg, spinal cord stimulator, intrathecal pump, or
             peripheral nerve stimulator) for the treatment of pain

          -  is pregnant or lactating
Clinical trial NCT00162123 (phase 2, status: completed)
Conditions: melanoma
ICD codes: C43.0, C43.31, D03.9, C43.51, C43.9, D03.0, C43.4
Drugs: ipilimumab
SMILES: COC1=CC=CC=C1OCC(O)CO
Eligibility criteria:

        For more information regarding BMS clinical trial participation, please visit
        www.BMSStudyConnect.com

        Key Inclusion Criteria

          -  Diagnosis of advanced melanoma

          -  Prior treatment in a prespecified prior/parent ipilimumab study

          -  Men and women 18 years of age and older

        First Reinduction:

          -  No unacceptable toxicity (except select reversible immune-related adverse events)
             requiring ipilimumab discontinuation

          -  Had experienced documented progressive disease after expanded clinical benefit

        Extended Maintenance

          -  Received ipilimumab at any dose in a parent study

          -  Achieved expanded clinical benefit at the time of entry to current study

        Follow-up:

          -  Received ipilimumab at any dose in a closing parent study

          -  Deemed ineligible for reinduction or extended maintenance treatment or refused
             treatment as reinduction or extended maintenance at the time of screening in the
             current study, but consented to follow-up

        Key Exclusion Criteria

          -  Prior treatment with a CD137 agonist or a cytotoxic T-lymphocyte antigen 4 inhibitor
             or agonist, other than ipilimumab

          -  Primary ocular or mucosal melanoma